LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
2 min read Premium comments
CONMED Corporation3Q26 financial resultsconference callwebcast
To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call webcast can also be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Contacts
CONMED Corporation
Investor Relations
IR@conmed.com
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
CONMED Corporation announced its third-quarter 2026 financial results will be reported on October 28, 2026, followed by a management conference call. This event is crucial for investors and market analysts to assess CONMED's financial health, operational performance, and strategic execution within the competitive medical technology sector, influencing market valuation and future investment decisions.
- The announcement provides a key opportunity for stakeholders to evaluate CONMED's Q3 2026 market performance.
- The conference call and webcast offer direct insights into management's strategic outlook and operational commentary.
PhD Lens: Clinical and outcomes impact
This article announces CONMED Corporation's upcoming third-quarter 2026 financial results and associated conference call. It details the schedule for the corporate financial disclosure, including webcast and telephone access. The release, however, does not provide any information regarding specific product mechanisms, materials science, clinical evidence, patient outcomes, or safety data related to CONMED's medical technologies.
- The article focuses solely on the timing and logistics of CONMED's corporate financial reporting.
- No scientific, clinical, or technical data concerning medical devices or surgical procedures is presented.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.